Wisdomly❦
Science

Bad Pharma

Ben Goldacre · 2012 · 10 ideas · 10 min

Roughly half of all clinical trial results are never published, and because unflattering results are the ones most likely to disappear, doctors are routinely making decisions on a systematically biased slice of the evidence.

Start reading♡ Save

Why this book

Goldacre's central claim is that modern medicine's evidence base is far less trustworthy than doctors, regulators, and patients generally assume, not because individual trials are typically faked, but because the overall system allows researchers and drug companies to conduct many trials and then selectively publish only the ones that make a treatment look good. Since positive results are roughly twice as likely to see publication as negative ones, the medical literature that doctors rely on to prescribe treatments is quietly, systematically skewed toward flattering conclusions — even for drugs that people are taking today.

This matters far beyond an academic technicality: Goldacre traces specific cases, such as the antidepressant reboxetine, where pooling all conducted trials (including previously unpublished ones) revealed a drug performing far worse, with more side effects, than the published literature alone suggested. Because most prescriptions each year are for older drugs, missing historical trial data isn't a problem that only affects new medicines — it distorts everyday treatment decisions happening right now, and it has persisted for decades despite being well documented among researchers.

Who should read it

This is essential for clinicians, medical students, health journalists, and any patient who wants to understand why a drug's reputation in practice sometimes diverges from its published trial record. Readers uninterested in the mechanics of clinical research and regulatory policy may find its detailed case studies more technical than they want.

About the author

Ben Goldacre is a British physician, academic, and science writer known for his work on evidence-based medicine and for co-founding the AllTrials campaign advocating full clinical trial transparency.

The ideas

01Roughly half of conducted clinical trials are never published02The reboxetine case shows exactly how selective publication distorts a drug's real profile03Industry-funded trials are measurably more likely to produce favorable results04Trial registries were supposed to fix this and largely failed to05Clinical study reports contain far more detail than the papers doctors actually read06Even national health assessors can't access the data they need07First-in-human trials frequently go unpublished, hiding safety signals08Missing data harms trial participants who believed they were contributing to knowledge09The AllTrials campaign asked for something modest, and it was still resisted10Perfect information about drug effectiveness would make drugs behave like commodities
medicinescienceevidenceregulationpharmaceutical-industrycritical-thinking
About this summary. Wisdomly re-expresses a book's ideas, arguments, and structure in our own words — nothing here is the author's text. Summaries are a map, not the territory: if the ideas land, the full book is worth your money and your evenings.